Pipeline And Milestones
Breaking Boundaries Engineering The Future of Targeted Medicines
Platform | Candidate | Program Area | Pre-Clinical Phase 1 Phase 2 Phase 3 | Status | Partner | Next Milestone |
---|---|---|---|---|---|---|
Gene-Based Therapy | Ofra-Vec (ofranergene obadenovec: 'VB-111') | Platinum Resistant Ovarian Cancer (PROC) | Status: Fully Enrolled | Fully Enrolled | ![]() | PFS Readout (Primary Endpoint) - 2H22 OS Readout (Primary Endpoint) - 2023 |
Recurrent Glioblastoma | Status: Recruiting | Recruiting | Preliminary Data - 2022 | |||
Colorectal Cancer | Status: Recruiting | Recruiting | Preliminary Data - 2022 | |||
Monoclonal Antibodies | VB-601 | Anti-inflammatory | Status: IND Enabling Studies | IND Enabling Studies | Wholly-owned | First in Human - 2H22 |